Given the diverse clinical scenarios in HER2-positive breast cancer, including neoadjuvant, adjuvant, and metastatic settings, this review aims to systematically evaluate the efficacy and safety of combining pertuzumab, trastuzumab, and docetaxel. This evidence concerns the gene ERBB2 and breast cancer.